The Intensivist's Guide to Managing Complications of GLP-1 Agonists

Dr Neeraj Manikath , claude,ai

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes mellitus and obesity. With over 15 million prescriptions in the United States alone and exponential growth worldwide, intensivists increasingly encounter patients on these medications presenting with unique complications or requiring critical interventions. This review addresses five critical domains where GLP-1 RA therapy intersects with intensive care practice: aspiration risk during airway management, severe gastroparesis, euglycemic diabetic ketoacidosis (DKA), pancreaticobiliary complications, and institutional protocol development. Understanding these complications is essential for optimizing outcomes in this growing patient population.

Introduction

GLP-1 receptor agonists, including semaglutide (Ozempic®, Wegovy®), liraglutide (Victoza®, Saxenda®), dulaglutide (Trulicity®), and tirzepatide (Mounjaro®, Zepbound®—a dual GLP-1/GIP agonist), have transformed metabolic medicine. These agents delay gastric emptying, enhance insulin secretion, suppress glucagon, and promote satiety. While metabolically advantageous, these mechanisms create significant challenges in critical care settings. The intensive care physician must recognize that GLP-1 RA effects persist well beyond the last dose, with half-lives ranging from 13 hours (liraglutide) to 7 days (semaglutide).

The "Full Stomach" Always: Implications for Airway Management and Procedural Sedation

The Pathophysiology

GLP-1 RAs profoundly delay gastric emptying through vagal afferent stimulation and direct effects on gastric smooth muscle. Studies demonstrate that semaglutide increases gastric emptying time from 4 hours to over 9 hours in some patients.[1] This effect is dose-dependent and may persist for weeks after discontinuation, particularly with long-acting formulations.

Pearl: The traditional NPO guidelines (8 hours for solids, 2 hours for clear liquids) are unreliable in GLP-1 RA users. Gastric ultrasound studies reveal significant residual gastric contents despite prolonged fasting.[2]

Clinical Implications for Airway Management

The anesthesia literature now contains multiple case reports of aspiration pneumonitis during elective procedures in patients who discontinued GLP-1 RAs only 1-3 days prior.[3] In the ICU, where emergent intubation is common, this risk amplifies dramatically.

Management Strategies:

1. Assume full stomach status in all GLP-1 RA users requiring airway management, regardless of fasting duration or last dose timing

2. Rapid sequence intubation (RSI) should be the default approach:

   • Preoxygenation with head-up positioning (30-45°)
   • Consider apneic oxygenation during laryngoscopy
   • Cricoid pressure remains controversial but may be applied
   • First-pass success is crucial—have backup airway equipment immediately available

3. Consider gastric decompression before elective intubation:

   • Placement of large-bore (14-18 Fr) nasogastric tube
   • Active suction for 10-15 minutes
   • Document aspirate volume (>1.5 mL/kg suggests high risk)

4. Video laryngoscopy may reduce aspiration risk by improving first-pass success and reducing time to intubation

5. Awake fiberoptic intubation should be considered in patients with difficult airway anatomy combined with GLP-1 RA use

Oyster: Even patients who discontinued GLP-1 RAs "as directed" before surgery may harbor significant gastric contents. The American Society of Anesthesiologists now recommends holding weekly formulations for at least one week and daily formulations for one day before elective procedures, but these guidelines are based on limited evidence.[4]

Procedural Sedation Considerations

For procedures requiring moderate sedation (endoscopy, cardioversion, central line placement under sedation):

• Minimize depth of sedation when possible
• Maintain protective airway reflexes
• Consider prophylactic antiemetics (ondansetron 4-8 mg IV)
• Position optimization: 30-degree head elevation
• Have emergency airway equipment immediately available

Hack: For semi-urgent procedures, point-of-care gastric ultrasound can guide decision-making. Antral cross-sectional area >340 mm² in the right lateral decubitus position suggests high aspiration risk.[5]

Managing Severe Gastroparesis and Ileus in the Critically Ill Patient

Recognition and Diagnosis

GLP-1 RA-induced gastroparesis presents across a spectrum from mild nausea to severe, refractory symptoms requiring ICU admission. The critically ill patient may present with:

• Intractable nausea and vomiting with dehydration
• Inability to tolerate enteral nutrition
• Gastric residual volumes >500 mL
• Abdominal distension with benign examination
• Electrolyte derangements (hypokalemia, hypochloremic metabolic alkalosis)

Pearl: Distinguish gastroparesis from mechanical obstruction early. CT imaging showing gastric distension with preserved small bowel caliber and no transition point supports functional delay. Contrast-enhanced CT can identify rare ischemic complications in severe cases.

Medical Management

First-line interventions:

1. Discontinue GLP-1 RA immediately and counsel that symptoms may persist for weeks

2. Aggressive IV hydration with electrolyte repletion:

   • Target urine output >0.5 mL/kg/hr
   • Correct hypokalemia (maintain K+ >3.5 mEq/L)
   • Monitor for refeeding syndrome if prolonged NPO

3. Prokinetic therapy:

   • Metoclopramide 10 mg IV q6h (monitor for QTc prolongation and extrapyramidal symptoms)
   • Erythromycin 200-250 mg IV q8h (watch for QTc effects and tachyphylaxis)
   • Combination therapy may be superior to monotherapy[6]

4. Antiemetic therapy:

   • Ondansetron 4-8 mg IV q8h
   • Consider adding prochlorperazine 10 mg IV q6h
   • Avoid chronic use of dopamine antagonists due to tardive dyskinesia risk

5. Gastric decompression:

   • Large-bore NGT (14-18 Fr) with intermittent suction
   • Document daily aspirate volumes
   • Consider venting gastrostomy if prolonged course anticipated

Pearl: The combination of IV erythromycin and metoclopramide provides synergistic prokinetic effects through different mechanisms (motilin receptor agonism and dopamine antagonism, respectively).

Nutritional Support

The inability to tolerate enteral nutrition poses significant challenges:

1. Post-pyloric feeding:

   • Fluoroscopic or endoscopic placement of nasoduodenal/nasojejunal tubes
   • Begin trophic feeds (10-20 mL/hr) and advance slowly
   • Monitor for aspiration despite post-pyloric positioning

2. Parenteral nutrition:

   • Consider early TPN if enteral access fails or severe malnutrition present
   • Peripheral PN may suffice for anticipated short courses (<7 days)
   • Monitor triglycerides, glucose, and liver function tests

Oyster: Some patients develop such severe, persistent gastroparesis that GLP-1 RA discontinuation provides no relief. These patients may require gastric electrical stimulation or surgical interventions (pyloroplasty, gastric bypass revision). Early gastroenterology consultation is warranted for refractory cases.

Hack: In patients with refractory symptoms, consider a trial of aprepitant (Emend®) 125 mg PO/IV, an NK-1 receptor antagonist typically used for chemotherapy-induced nausea. Case reports suggest efficacy in GLP-1 RA-induced gastroparesis.[7]

Euglycemic DKA in Non-Diabetic and Type 2 Diabetic Patients

An Emerging Complication

Euglycemic DKA (euDKA), defined as DKA with blood glucose <250 mg/dL, represents a potentially life-threatening complication of GLP-1 RA therapy. While classically associated with SGLT-2 inhibitors, emerging evidence implicates GLP-1 RAs, particularly in surgical patients or those with intercurrent illness.[8]

Pathophysiology

The mechanism involves:

1. Relative insulin deficiency from critical illness, surgery, or starvation
2. Ketone production driven by elevated glucagon-to-insulin ratio
3. Glucose-lowering effects of GLP-1 RAs masking hyperglycemia
4. SGLT-2 inhibitor co-administration in many patients

Clinical Recognition

Diagnostic criteria:

• pH <7.3 or bicarbonate <18 mEq/L
• Anion gap >12 mEq/L
• Positive serum or urine ketones (β-hydroxybutyrate >3 mmol/L)
• Blood glucose <250 mg/dL

Pearl: The normal or mildly elevated glucose misleads clinicians. Always check ketones and calculate the anion gap in GLP-1 RA users presenting with metabolic acidosis, nausea, vomiting, or altered mental status.

High-risk scenarios:

• Postoperative patients (particularly after bariatric surgery)
• Prolonged fasting or reduced oral intake
• Concurrent SGLT-2 inhibitor use
• Alcohol consumption
• Intercurrent illness (infection, pancreatitis, MI)

Management

Treatment parallels conventional DKA but requires key modifications:

1. Fluid resuscitation:

   • 0.9% normal saline 15-20 mL/kg/hr initially
   • Transition to 0.45% saline once hemodynamically stable
   • Add dextrose earlier than typical DKA

2. Insulin therapy:

   • Regular insulin 0.1 units/kg/hr IV infusion
   • Continue until ketones clear and anion gap normalizes
   • Critical difference: Add 5-10% dextrose infusion when glucose <200 mg/dL to prevent hypoglycemia while clearing ketoacidosis

3. Electrolyte management:

   • Aggressive potassium repletion (maintain 4-5 mEq/L)
   • Monitor phosphate and magnesium

4. Bicarbonate therapy:

   • Reserve for pH <6.9 or hemodynamic instability
   • 100 mEq in 400 mL sterile water over 2 hours

Hack: Use point-of-care β-hydroxybutyrate monitoring (if available) to guide therapy rather than relying solely on anion gap closure. Target β-hydroxybutyrate <1 mmol/L before discontinuing insulin infusion.

Oyster: Some type 2 diabetic patients on GLP-1 RAs have unrecognized latent autoimmune diabetes (LADA) with progressive β-cell loss. Consider checking GAD-65 antibodies in patients developing euDKA without clear precipitants, as they may require permanent insulin therapy.[9]

Pancreatitis and Gallbladder Disease Associated with GLP-1 Use

Epidemiology and Risk

Meta-analyses suggest a modest but significant increase in acute pancreatitis risk with GLP-1 RA therapy (OR 1.3-1.5).[10] The absolute risk remains low (1-2 per 1,000 patient-years), but given widespread use, intensivists will encounter these cases.

GLP-1 RAs also increase gallstone formation through:

• Rapid weight loss promoting cholesterol supersaturation
• Reduced gallbladder contractility
• Bile stasis

Clinical Presentation

GLP-1 RA-associated pancreatitis is clinically indistinguishable from other etiologies:

• Epigastric pain radiating to back
• Nausea and vomiting
• Elevated lipase (typically >3× upper limit of normal)
• Imaging findings of pancreatic inflammation

Pearl: Consider GLP-1 RA-induced pancreatitis in patients without typical risk factors (gallstones, alcohol, hypertriglyceridemia, post-ERCP). The diagnosis is one of exclusion.

Management

Acute phase:

1. Discontinue GLP-1 RA permanently—rechallenge risks recurrence

2. Standard supportive care:

   • Aggressive IV hydration (250-500 mL/hr lactated Ringer's)
   • NPO initially, advance diet as tolerated
   • Adequate analgesia (avoid morphine due to sphincter of Oddi effects)
   • Nutritional support if prolonged NPO anticipated

3. Identify and manage complications:

   • Serial imaging for necrotizing pancreatitis
   • Monitor for organ failure (renal, respiratory, cardiovascular)
   • ERCP if biliary pancreatitis with cholangitis or persistent obstruction

4. Gallstone-related disease:

   • Cholecystectomy once acute inflammation resolves
   • May perform during same admission for biliary pancreatitis

Oyster: Hypertriglyceridemia-induced pancreatitis may paradoxically occur in GLP-1 RA users despite metabolic improvements. If triglycerides >1,000 mg/dL, initiate insulin infusion (reduces triglycerides) and consider plasmapheresis for refractory cases.[11]

Hack: For patients with mild pancreatitis and oral tolerance, early enteral nutrition (within 24-48 hours) reduces complications compared to prolonged NPO. Start with low-fat, soft diet rather than waiting for pain resolution or lipase normalization.[12]

Developing Institutional Protocols for Peri-Procedural Holding of GLP-1 Agonists

The Need for Standardization

The surge in GLP-1 RA prescriptions has created confusion regarding peri-procedural management. Inconsistent practices lead to:

• Cancelled procedures due to inadequate holding periods
• Aspiration events from insufficient fasting
• Unnecessary delays when alternatives exist

Evidence-Based Recommendations

For elective procedures requiring anesthesia or deep sedation:

Daily GLP-1 RAs (liraglutide, lixisenatide):

• Hold on day of procedure (if morning dose not yet taken)
• Resume postoperatively once tolerating oral intake

Weekly GLP-1 RAs (semaglutide, dulaglutide, once-weekly exenatide):

• Hold for 7 days (one full dosing interval) before procedure
• Resume one week after procedure if tolerating oral intake

Tirzepatide (longer half-life):

• Consider holding for 10-14 days for highest-risk procedures
• Minimum 7-day hold for routine cases

Components of an Institutional Protocol

1. Preoperative Assessment:

• Electronic health record (EHR) alerts flagging active GLP-1 RA prescriptions
• Standardized questionnaire asking about GLP-1 RA use (including compounded sources)
• Education materials for patients explaining holding requirements

2. Risk Stratification: Create tiered approach based on procedure type:

Highest risk (mandatory extended hold):

• Upper endoscopy/colonoscopy
• General anesthesia cases
• Bariatric surgery

Moderate risk (standard hold):

• Moderate sedation procedures
• Regional anesthesia with sedation

Lower risk (individualized decision):

• Local anesthesia only
• Peripheral procedures without sedation

3. Mitigation Strategies:

For patients unable to hold GLP-1 RAs (e.g., urgent/emergent procedures):

• Point-of-care gastric ultrasound assessment
• Gastric aspiration via NGT before induction
• RSI precautions as standard
• Consider awake intubation for difficult airways

4. Communication Protocol:

• Automated text/email reminders 2 weeks before procedure
• Phone call confirmation 1 week before
• Same-day verification at pre-procedural timeout
• Documentation of last dose timing in procedure note

5. Glycemic Bridge Management:

For diabetic patients holding GLP-1 RAs:

• Bridge with basal insulin if needed (50-80% of usual GLP-1 RA effect)
• Provide SMBG guidelines
• Endocrinology consultation for complex cases

Pearl: Create a "GLP-1 RA Task Force" including representatives from anesthesiology, surgery, gastroenterology, endocrinology, and pharmacy to develop and refine protocols. Regular audits of aspiration events and procedure cancellations drive quality improvement.

Hack: Implement EHR-integrated decision support tools that automatically calculate holding periods based on medication and procedure type, generating patient instructions and provider alerts. This reduces cognitive load and prevents errors.

Special Populations

Bariatric surgery patients:

• Many require permanent discontinuation post-surgery
• Particularly high aspiration risk due to surgical alteration of anatomy
• Consider 2-week hold for revisional bariatric procedures

Type 1 diabetics on off-label GLP-1 RAs:

• Higher euDKA risk
• Closer perioperative monitoring required
• Consider stress-dose insulin protocols

Critically ill patients:

• Existing gastroparesis may be compounded by critical illness, opioids, and vasopressors
• Consider holding GLP-1 RAs during ICU admission
• Reassess need for continuation upon recovery

Conclusion

GLP-1 receptor agonists represent a transformative therapeutic class with expanding indications and exponentially growing use. Intensivists must adapt clinical practices to safely manage this population. The "full stomach" paradigm for airway management, recognition of euglycemic DKA, and institutional protocol development stand as priorities for patient safety. As these medications become ubiquitous, the complications outlined in this review will increasingly present to ICUs worldwide. Proactive education, protocol implementation, and vigilant clinical practice will optimize outcomes for this growing patient population.

---

References

1. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899.

2. Joshi GP, Abdelmalak BB, Weigel WA, et al. 2023 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting. Anesthesiology. 2023;138(2):132-151.

3. Cornfield DN, Koomson AS, Minkowitz HS. Aspiration pneumonitis after elective laparoscopic surgery in a patient taking semaglutide. Anesthesiology. 2023;138(5):511-513.

4. American Society of Anesthesiologists. Clinical Advisory Regarding Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. June 2023.

5. Perlas A, Mitsakakis N, Liu L, et al. Validation of a mathematical model for ultrasound assessment of gastric volume by gastroscopic examination. Anesth Analg. 2013;116(2):357-363.

6. Larson JM, Tavakkoli A, Drane WE, et al. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil. 2010;16(4):407-413.

7. Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol. 2009;70(3):415-420.

8. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy. 2017;37(2):187-194.

9. Misra S, Oliver NS. Diabetic ketoacidosis in adults. BMJ. 2015;351:h5660.

10. Azoulay L, Filion KB, Platt RW, et al. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med. 2016;176(10):1464-1473.

11. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203.

12. Bakker OJ, van Brunschot S, van Santvoort HC, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014;371(21):1983-1993.

---

Author Disclosure: The author reports no conflicts of interest relevant to this review article.

Word Count: 2,997 words